Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | vacuolar-type proton translocating pyrophosphatase 1 | 0.0683 | 0.5 | 0.5 |
Toxoplasma gondii | V-type H(+)-translocating pyrophosphatase VP1 | 0.0683 | 0.5 | 0.5 |
Plasmodium falciparum | V-type H(+)-translocating pyrophosphatase, putative | 0.0683 | 0.5 | 0.5 |
Trypanosoma brucei | Pyrophosphate-energized vacuolar membrane proton pump 1 | 0.0683 | 0.5 | 0.5 |
Plasmodium falciparum | V-type K+-independent H+-translocating inorganic pyrophosphatase | 0.0683 | 0.5 | 0.5 |
Trypanosoma cruzi | Vacuolar proton pyrophosphatase 1, putative | 0.0683 | 0.5 | 0.5 |
Trypanosoma brucei | Pyrophosphate-energized vacuolar membrane proton pump 2, putative | 0.0683 | 0.5 | 0.5 |
Plasmodium vivax | V-type H(+)-translocating pyrophosphatase, putative | 0.0683 | 0.5 | 0.5 |
Plasmodium vivax | vacuolar-type H+ pumping pyrophosphatase, putative | 0.0683 | 0.5 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.